Last reviewed · How we verify
Ibandronate+alfacalcidol+calcium
Ibandronate+alfacalcidol+calcium is a Bisphosphonate + active vitamin D + mineral supplement combination Small molecule drug developed by Chinese University of Hong Kong. It is currently FDA-approved for Osteoporosis treatment and prevention, Bone loss associated with postmenopausal women or glucocorticoid use. Also known as: Bonviva, placebo Bonviva.
This combination therapy inhibits bone resorption via bisphosphonate action while simultaneously promoting bone mineralization through active vitamin D and calcium supplementation.
This combination therapy inhibits bone resorption via bisphosphonate action while simultaneously promoting bone mineralization through active vitamin D and calcium supplementation. Used for Osteoporosis treatment and prevention, Bone loss associated with postmenopausal women or glucocorticoid use.
At a glance
| Generic name | Ibandronate+alfacalcidol+calcium |
|---|---|
| Also known as | Bonviva, placebo Bonviva |
| Sponsor | Chinese University of Hong Kong |
| Drug class | Bisphosphonate + active vitamin D + mineral supplement combination |
| Target | Farnesyl pyrophosphate synthase (ibandronate); vitamin D receptor (alfacalcidol); calcium channels (calcium) |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
Ibandronate is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Alfacalcidol (1-alpha-hydroxyvitamin D3) enhances intestinal calcium absorption and promotes osteoblast differentiation, while calcium provides the mineral substrate for bone formation. Together, these agents work synergistically to increase bone mineral density and reduce fracture risk.
Approved indications
- Osteoporosis treatment and prevention
- Bone loss associated with postmenopausal women or glucocorticoid use
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Musculoskeletal pain
- Hypercalcemia (with excessive supplementation)
- Osteonecrosis of the jaw (rare)
- Atypical fractures (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibandronate+alfacalcidol+calcium CI brief — competitive landscape report
- Ibandronate+alfacalcidol+calcium updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI
Frequently asked questions about Ibandronate+alfacalcidol+calcium
What is Ibandronate+alfacalcidol+calcium?
How does Ibandronate+alfacalcidol+calcium work?
What is Ibandronate+alfacalcidol+calcium used for?
Who makes Ibandronate+alfacalcidol+calcium?
Is Ibandronate+alfacalcidol+calcium also known as anything else?
What drug class is Ibandronate+alfacalcidol+calcium in?
What development phase is Ibandronate+alfacalcidol+calcium in?
What are the side effects of Ibandronate+alfacalcidol+calcium?
What does Ibandronate+alfacalcidol+calcium target?
Related
- Drug class: All Bisphosphonate + active vitamin D + mineral supplement combination drugs
- Target: All drugs targeting Farnesyl pyrophosphate synthase (ibandronate); vitamin D receptor (alfacalcidol); calcium channels (calcium)
- Manufacturer: Chinese University of Hong Kong — full pipeline
- Therapeutic area: All drugs in Bone metabolism / Osteoporosis
- Indication: Drugs for Osteoporosis treatment and prevention
- Indication: Drugs for Bone loss associated with postmenopausal women or glucocorticoid use
- Also known as: Bonviva, placebo Bonviva
- Compare: Ibandronate+alfacalcidol+calcium vs similar drugs
- Pricing: Ibandronate+alfacalcidol+calcium cost, discount & access